This page is alzhub.org's plain-English summary of a published study, not the paper itself. It is generated from the record we hold for this study, sourced and linked below — check the original for the full text and methods.

30/100

✓ Peer-reviewed alzhub usefulness score 30 out of 100. Tau biomarkers

Topic: Amyloid, tau and blood-test diagnosis

Introduction Some studies have shown that CSF amyloid-beta 1-42 (Aβ₁₋₄₂), total tau (T-tau) and tau phosphorylated at threonine 181 (P-tau(181p)) proteins are useful diagnostic markers for distinguishing between clinically stable mild cognitive impairment (MCI) patients and those who will develop Alzheimeŕs disease (AD). Our objective was to test the ability of this technique to discriminate in our cohort of MCI patients, according to the clinical outcome, one year after the lumbar puncture. Material and methods A total of 36 MCI patients were included from the local hospital memory clinic.

Key findings

Our objective was to test the ability of this technique to discriminate in our cohort of MCI patients, according to the clinical outcome, one year after the lumbar puncture.
Material and methods A total of 36 MCI patients were included from the local hospital memory clinic.
Using INNO-BIA Alzbio-3 reagents from Innogenetics, we measured CSF Aβ₁₋₄₂, T-tau and P-tau(181p) proteins, and calculated the T-tau/Aβ₁₋₄₂ y P-tau(181p)/Aβ₁₋₄₂ ratios.
This project was approved by the local ethics committee.

Why it matters

In this small study of 36 patients with mild cognitive impairment, those with reduced cerebrospinal fluid amyloid-beta 1-42 progressed rapidly to Alzheimer's disease one year after lumbar puncture. This is prognostic information from a small sample and does not report any treatment, cure, or prevention.

New to this subject? Start with our plain-English guide: Blood tests & biomarkers →

Study details

Participants36
Evidence strengthModerate

How this study scored 30/100

Published in a peer-reviewed journal. Scored zero for study design, effect reported and randomised / blinded because the record does not state it.

Component	Points	Why
Journal tier	7 / 10	Tier 3 — peer-reviewed journal (Neurologia (Barcelona, Spain))
Journal's citation record	0 / 4	Neurología: journal h-index 54 (OpenAlex, 2026-10-29)
Study design	0 / 12	No study design recorded — scores zero, not guessed (not stated in the record — scored 0)
Strength of evidence	3 / 5	Rated “moderate” in our summary
Peer-review validation	10 / 10	Peer-reviewed. Published as an article in a named peer-reviewed journal.
How recent	1 / 5	2012 — within 20 year(s) of the newest study here
Sample size	1 / 4	36 participants
Effect reported	0 / 3	No effect size reported — scores zero (not stated in the record — scored 0)
Studied in people	3 / 3	Studied in people (participant count stated)
Randomised / blinded	0 / 2	No randomisation or blinding stated — scores zero (not stated in the record — scored 0)
Times cited	1 / 7	Cited 3 times (OpenAlex, 2026-10-10)
Citations per year	0 / 5	0.2 citations a year over 16 year(s) since 2012
Impact for its field and year	1 / 6	Cited 0.2× the average for papers of its field and year (OpenAlex FWCI)
Cited by studies here	0 / 6	No other study in this library cites it
Still being cited	0 / 4	Cited 0 times in 2024–2026 (2026 still in progress; OpenAlex)
Senior author's track record	1 / 4	Last-listed author Carlos Leiva-Santana: h-index 8 (OpenAlex, whole career)
Institution's track record	0 / 3	Hospital General Universitario de Alicante Doctor Balmis: institution h-index 210 (OpenAlex)
Multi-centre collaboration	0 / 3	OpenAlex lists 1 institution(s) in 1 country — scores zero (affiliation lists can be incomplete)
Indexed in PubMed	2 / 2	Indexed in PubMed (PMID 21621878)
Free to read	0 / 2	Behind a paywall — scores zero
Total	30 / 100	—

What each of these 20 components measures, and what this score is not →

Read the original

Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).

Cite this study APA, Vancouver, BibTeX · download .bib or .ris

Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record names 8 authors; APA and Vancouver show the first six, BibTeX and the downloads carry all of them. Check the citation against the original before you use it.

APA 7th

Monge-Argilés, J. A., Sánchez-Payá, J., Muñoz-Ruiz, C., Pampliega-Pérez, A., Gómez-López, M. J., Rodríguez Borja, E., et al. (2012). [Patients with mild cognitive impairment and a reduced CSF Aβ₁₋₄₂ protein progress rapidly to Alzheimer's disease]. Neurologia (Barcelona, Spain). https://doi.org/10.1016/j.nrl.2011.03.014

Vancouver

Monge-Argilés JA, Sánchez-Payá J, Muñoz-Ruiz C, Pampliega-Pérez A, Gómez-López MJ, Rodríguez Borja E, et al. [Patients with mild cognitive impairment and a reduced CSF Aβ₁₋₄₂ protein progress rapidly to Alzheimer's disease]. Neurologia (Barcelona, Spain). 2012. doi:10.1016/j.nrl.2011.03.014. PMID: 21621878.

BibTeX

@article{mongeargiles2012-21621878,
  author  = {Monge-Argilés, J. A. and Sánchez-Payá, J. and Muñoz-Ruiz, C. and Pampliega-Pérez, A. and Gómez-López, M. J. and Rodríguez Borja, E. and Montoya-Gutiérrez, J. and Leiva-Santana, C.},
  title   = {{[Patients with mild cognitive impairment and a reduced CSF Aβ₁₋₄₂ protein progress rapidly to Alzheimer's disease]}},
  journal = {Neurologia (Barcelona, Spain)},
  year    = {2012},
  doi     = {10.1016/j.nrl.2011.03.014},
  pmid    = {21621878},
  url     = {https://doi.org/10.1016/j.nrl.2011.03.014}
}

Studies this one cites

Referenced by this study and also in the alzhub library, so you can read them here.

Related studies in Tau biomarkers

Also tagged “biomarkers”

821 studies in the library carry the topic tag “biomarkers”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 821 tagged studies.

Similar studies

More on Tau biomarkers

See all studies in Tau biomarkers →